Veracyte, Inc. - Common Stock (VCYT)

Competitors to Veracyte, Inc. - Common Stock (VCYT)

Exact Sciences Corporation 

Exact Sciences Corporation specializes in molecular diagnostics and is particularly known for its non-invasive colorectal cancer screening test, Cologuard. The company competes with Veracyte by offering innovative diagnostic solutions that focus on early detection and preventing cancer, leveraging its technology and extensive data analytics in the oncology space. While both companies focus on cancer diagnostics, Exact Sciences has a broader portfolio that includes tests for both early and non-invasive screening.

Fulgent Genetics, Inc. 

Fulgent Genetics offers a broad range of genetic testing services, including oncology, which puts it in competition with Veracyte. Both companies aim to provide diagnostic solutions in the oncology space, but Fulgent boasts a more extensive menu of customizable tests that can appeal to various patient needs. The ability to quickly adapt its offerings and a focus on pricing can provide Fulgent with a competitive advantage in accessibility to genetic testing procedures relative to Veracyte's specialized focus.

Guardant Health, Inc. 

Guardant Health is a leader in blood-based cancer diagnostics and precision oncology, providing comprehensive genomic profiling tests for advanced cancer detection and monitoring. Guardant competes with Veracyte primarily in oncology diagnostics with a significant emphasis on liquid biopsy solutions, which offer a less invasive testing approach. Guardant’s proprietary technologies and partnerships with oncologists provide it with an advantage in terms of market presence and repeat usage in clinical settings.

Myriad Genetics, Inc. 

Myriad Genetics is known for its hereditary cancer testing and precision medicine, providing a suite of testing for genetic variants indicating cancer risks. Competing in the oncology diagnostics market with Veracyte, Myriad has leveraged its strong brand reputation and established clinical guidelines for many of its tests, which may give it an advantage in terms of physician familiarity and integration into clinical pathways. Myriad's comprehensive offerings in hereditary cancer predisposition testing add another layer to the services that clients can access.

NeoGenomics, Inc. 

NeoGenomics focuses on cancer-focused genetic testing and diagnostics, providing laboratory services to hospitals and outreach programs. The company competes with Veracyte through its wide range of tests used for various types of cancer, including histology and molecular testing. NeoGenomics has established a strong reputation and clinical partnerships, giving it a competitive edge in the lab services sector and making it a key player in cancer testing alongside Veracyte's focus on solid tumor diagnostics.